Cargando…
Streamlining R&D permission for substantial amendments to oncology clinical trials at an NHS site: a case study
Autores principales: | I'Anson, David, Smith, Amy, Aslam, Natasha, Gyertson, Kylie, Sidhu, Rajinder, Agathou, Smaragda, Gill, Ashparan, Whelan, Jeremy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660122/ http://dx.doi.org/10.1186/1745-6215-16-S2-P190 |
Ejemplares similares
-
The role of an in-house audit group as an innovative tool to review clinical trials
por: Trivedi, Shivali, et al.
Publicado: (2015) -
Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology
por: Porter, Charles, et al.
Publicado: (2022) -
Diphtheria
por: I’Anson, R. W.
Publicado: (1861) -
One stop or full stop? The continuing challenges for researchers despite the new streamlined NHS research governance process
por: Thompson, Andrew GH, et al.
Publicado: (2010) -
Common Clinical Trial Amendments, why they are submitted and how they can be avoided: a mixed methods study on NHS UK Sponsored Research (Amendments Assemble)
por: Joshi, Shivam
Publicado: (2023)